MDWD Stock — MediWound Ltd.: Cash, EV, Pipeline

Share price

$13.40

Market cap

$173.0M

Cash

$4.8M

Enterprise value

$168.2M

Balance sheet

Cash	$4.8M
Debt	$0.0M
Net cash	$4.8M
Enterprise value	$168.2M
Basic shares	12.9M shares
Fully diluted shares	16.5M shares
Fully diluted market cap	$221.3M
Cash per share	$0.37

Cash figures as of 2025-12-31. Database snapshot: 2026-09-21.

Price history

Loading MDWD daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	EscharEx (EX-03)	Phase 3	Venous Leg Ulcer (VLU)	Q2 2027
Feb 10 - Mar 23	EscharEx (EX-03)	Phase 2	Venus Leg Ulcers	—
Sep 12 - Oct 24	EX-03	Phase 2	Venous Leg Ulcer (VLU)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

NexoBrid

Approved · Active Modality: enzymatic debridement gel (bromelain-based)

Target eschar (proteolytic enzymatic debridement)

Partnerships Exclusive North America commercialization license and supply agreements with Vericel Corporation (May 2019; $17.5M upfront, $7.5M BLA-approval milestone, up to $125M sales milestones, mid-high single-digit to mid-teen tiered royalties).

Indications

Eschar removal in deep partial- and full-thickness thermal burns (Approved)

Status note Proteolytic enzyme-based gel for eschar removal in severe burns; approved in the U.S., Europe and other markets. U.S. launch via commercial partner Vericel was delayed by supply/CMC issues. A post-marketing U.S. Phase III trial satisfied an EMA post-marketing commitment. Label carries warnings for hypersensitivity reactions and pain.

EscharEx

Phase 3 · Active Modality: enzymatic debridement gel (proteolytic enzymes)

Target necrotic tissue (enzymatic debridement)

Indications

Chronic wounds (Phase 3)

Status note Proteolytic enzyme-based candidate for chronic wound debridement based on the company's patented enzymatic technology platform. Phase III clinical study ongoing; clinical batch supply manufactured at the company's site.

Per-asset detail extracted from the 20-F filed 2026-03-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	EscharEx (EX-03)
Lead indication	Venous Leg Ulcer (VLU)
Lead phase	Phase 3
Active trials	4

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06568627	Phase 3	Recruiting	Sponsor	MDWD	—	Venous Leg Ulcer (VLU)	Q2 2027
NCT06690177	Phase 2	Not yet recruiting	Sponsor	MDWD	—	Venus Leg Ulcers	—
NCT07692178	Phase 2	Not yet recruiting	Sponsor	MDWD	—	Venous Leg Ulcer (VLU)	—
NCT05157763	Phase 2	Recruiting	Sponsor	MDWD	—	Superficial Basal Cell Carcinoma; Nodular Basal Cell Carcinoma	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for MediWound Ltd on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Sphera Biotech	273,192	no change	0.57%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

MDWD — MediWound Ltd.